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Fifty-one patients with advanced germ cell malig-
nancy who had either failed to achieve complete
remission with initial cisplatin, vinblastine, and bleo-
mycin chemotherapy or who had relapsed after com-
plete response (CR) to this therapy and then proven
refractory on retreatment, were treated with etopo-
side (75 mg/m' for 3 days), dactinomycin (1 mg/m2
day 1), and methotrexate (30 mg/m2 day 1) (EAM)
every 3 weeks. Courses were continued until maxi-
mum response without empirical limit, and if com-
plete remission was achieved, two courses of consoli-
dation therapy were given before cessation of
treatment. Thirteen patients (25%) were complete
responders with residual masses containing fibrosis or
benign teratoma being subsequently resected in seven
patients. Two patients had persisting viable carci-
noma within residual masses that were completely
resected, leaving no evidence of disease (NED); the
combined CR plus NED rate was 29%. The only
DESPITE the success of intensive chemother-
apy in the treatment of advanced germ cell
cancer, some 20% to 30% of patients fail to
achieve complete remission and a further 10% to
15% relapse after completion of chemotherapy,
with the majority dying of progressive disease
within a few months of initiation of treatment.' 3
It has now been shown that several drugs have
activity in this refractory group of patients and
complete remissions with subsequent long-term
survival have occurred. 4 6 The most extensively
studied agent has been etoposide and this drug,
either alone or in combination with cisplatin and
ifosfamide, has achieved complete remission in
13% to 33% of patients who had received consid-
erable prior chemotherapy.s- 10 Some 25% to 50%
of these patients have continued free of disease
for periods in excess of 1 year.
In a large multiinstitutional Australian and
New Zealand study, the three-drug combination
of cisplatin, vinblastine, and bleomycin was em-
ployed as induction chemotherapy for patients
with advanced and metastatic germ cell cancer;
24% of patients failed to achieve complete remis-
pretreatment factor significantly influencing this re-
sponse rate was tumor volume. Toxicities were moder-
ate, with leukopenia being observed in 28% of
patients, but it was severe in only 2%. There was one
death from septicemia. Severe nausea and vomiting
occurred in only 9% of patients and treatment-related
stomatitis was observed in 42%. All patients achiev-
ing CR plus NED have been followed for a minimum of
5 years and no relapses have occurred, suggesting
that these patients are cured. Unlike other regimens of
salvage chemotherapy, this treatment program did
not contain cisplatin and it is contended that a
completely noncrossresistant drug regimen based on
etoposide provides the opportunity to further improve
the curability of patients with advanced germ cell
cancer.
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sion or no evidence of disease (NED) after
surgical resection of residual tumor and 12%
relapsed after initial complete response (CR).3
Recognizing the reported activity of etoposide,
an agent with a different mechanism of action to
the drugs already given and the potential for
other drugs to be also noncrossresistant to the
primary induction chemotherapy, the three-drug
combination of etoposide, dactinomycin, and
methotrexate (EAM) was studied in this refrac-
tory group of patients. The results of this study
are now reported.
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PATIENTS AND METHODS
From May 1979 to February 1983, 51 patients from 12
institutions in Australia and New Zealand were entered onto
the study. All patients had histologically proven germ cell
cancer with at least one site of measurable or evaluable
disease; in one patient elevation of the tumor markers
B-human chorionic gonadotropin (BHCG) and fetoprotein
(AFP) was present without other apparent disease. All
patients had received prior chemotherapy with cisplatin,
vinblastine, and bleomycin, given according to the previously
published regimen.3 Thirty-seven patients had not achieved a
complete remission or NED with this chemotherapy and had
disease that was considered surgically unresectable. Another
14 patients had recurrent tumors after CR to the prior
therapy and they were retreated with the same regimen, but
the disease proved unresponsive.
Before each cycle of chemotherapy, all patients had a
complete history and physical examination, chest x-ray, full
blood count including differential and platelets, biochemical
profile including serum creatinine, serum AFP, and plasma
BHCG. Abdominal and thoracic computed tomographic
(CT) and radionuclide scans were performed initially if
clinically indicated and if abnormal, repeated at six weekly
intervals during chemotherapy.
All patients received chemotherapy with etoposide 75
mg/m2 days 1, 2, and 3 by intravenous (IV) infusion over 1
hour, dactinomycin 1 mg/m 2 by IV injection day 1, and
methotrexate 30 mg/m2 by IV injection day 1. The regimen
was repeated at 21-day intervals. Courses were delayed by 1
week if the WBC count was less than 3,000/ML and/or the
platelet count was less than 100,000/uL. If the nadir WBC
count was less than 2,000/uL and/or the platelet count less
than 75,000/,1L, doses of all three drugs were reduced by
25% for the next course. Doses of methotrexate were reduced
if moderate or severe mucosal toxicity occurred.
The number of courses of chemotherapy given was deter-
mined by clinical and biochemical evidence of tumor response
without any empirical limit. If complete remission was
achieved, as defined by complete disappearance of all evi-
dence of disease and return to normal of elevated tumor
markers for at least 1 month, two further courses of chemo-
therapy were administered as consolidation and these pa-
tients were observed thereafter.
Patients with stable residual disease, providing previously
elevated tumor markers had returned to normal for at least 1
month, underwent surgical exploration and, wherever possi-
ble, resection of all residual abnormalities was undertaken. If
the resected specimens contained fibrosis or benign teratoma,
the patients were considered to be in complete remission,
received two courses of consolidation chemotherapy, and
were observed thereafter. If viable carcinoma was found and
considered completely removed, the patients were classified
as having NED, received two further courses of chemother-
apy, and were observed.
Patients were classified as achieving partial remission (PR)
when there was a more than 50% reduction in the sum of the
products of the longest diameter and its perpendicular for all
measurable sites, and included at least 90% reduction in the
pretreatment level of BHCG and AFP, when surgical resec-
tion was not undertaken or was incomplete, and lasted for at
least 1 month. These patients continued chemotherapy until
relapse occurred. All other patients were classified as having
either no change (NC) (ie, a decrease in disease parameters
that did not reach the criteria for a PR after three courses of
therapy) or progressive disease (PD) (when measurable
disease parameters increased in size by at least 25%) or when
there was the appearance of new lesions or increase by at least
one log in the level of BHCG or AFP. They were then
removed from study.
Relapse was defined as evidence of recurrent disease
clinically or radiographically or if a persistent rise in BHCG
and AFP by more than one log above normal values occurred
after CR or NED. Toxicities encountered with therapy were
classified according to World Health Organization (WHO)
criteria."
Durations of response and survival were calculated from
the date of initiation of EAM therapy until relapse, death, or
date of last follow-up. Response data were compared by the
X2 analysis. Durations of response and survival were com-
pared by log-rank analysis and survival curves constructed
according to the method of Kaplan-Meier.'2
RESULTS
Pretreatment characteristics of the patient
population are indicated in Table 1. All 51
patients entered were evaluable for response,
survival, and toxicity of therapy.
Table 2 presents the tumor response rates for
the total patient population and is divided accord-
ing to the pretreatment characteristics. Overall,
13 patients (25%) achieved complete remission.
Surgical resection of residual masses was per-
Table 1. Pretreatment Characteristics
Patient
Number
Total patient entry
Median age/yr (range)
Site of primary
Testicular
Extragonadal
Extent of disease*
Markers only
Cervical lymph node
Minimum lung plus abdomen
Advanced lung
Advanced abdomen
Advanced lung plus abdomen
Performance statust
0 to 1
2 to 3
Tumor markers
Elevated BHCG plus AFP
Histology
Embryonal cell
Teratocarcinoma
Choriocarcinoma
Embryonal plus teratocarcinoma
Mixed
51
30 (16 to 59)
42
9
1
1
4
10
13
22
39
12
25
11
11
2
17
10
*Criteria reported by Samuel et a.l."3
"tEastern Cooperative Oncology Group criteria.
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Table 2. Response Rates and Pretreatment Factors
Response
Number of Patients (%)
CR NED PR NC PD
Total patients 13 (25) 2 (4) 10(20) 7(14) 19(37)
Relapse patients 3 (21) 0 3 (21) 3 (21) 5 (37)
Site of primary tumor
Testicular 12(29) 1 (2) 9 (21) 4(10) 16(38)
Extragonadal 1 (11) 1 (11) 1 (11) 3(33) 3(33)
Extent of disease
Markers only 1 (100) 0 0 0 0
Cervical lymph node 1 (100) 0 0 0 0
Minimum lung plus abdomen 3 (75) 1 (25) 0 0 0
Advanced lung 0 0 3 (30) 2 (20) 5 (50)
Advanced abdomen 2 (15) 1 (8) 3 (23) 1 (8) 6 (46)
Advanced lung plus abdomen 6 (27) 0 4 (18) 4(18) 8 (37)
Performance status
Oto 1 13(33) 2 (5) 8 (21) 5 (13) 11(28)
2to 3 0 0 2 (17) 2 (17) 8 (66)
Tumor markers
Elevated BHCG plus AFP 3 (12) 0 8 (32) 5 (20) 9 (36)
Histology
Embryonal cell 2 (18) 0 0 3 (27) 6 (55)
Teratocarcinoma 3 (27) 1 (9) 3 (27) 1(9) 3 (27)
Choriocarcinoma 3(100) 0 0 0 0
Embryonal plus teratoca 4 (24) 1 (6) 5 (29) 2 (12) 5 (29)
Mixed 2 (20) 0 2 (20) 1(10) 5 (50)
Abbreviations: CR, complete response; NED, no evidence of disease; PR, partial response; NC, no change; PD, progressive disease.
formed after EAM therapy in seven of these
patients and revealed necrosis and fibrosis in one
and benign teratoma in six. In two patients viable
carcinoma within residual masses was com-
pletely resected, rendering these patients NED.
Thus, the combined CR plus NED rate was 29%.
Among the 14 patients who had initially re-
sponded to the prior chemotherapy and later
relapsed, three (21%) achieved CR with this
salvage chemotherapy.
The median number of chemotherapy courses
given to all patients was four (range, one to 11).
Of the 20 patients receiving five or more courses,
10 entered CR plus NED, indicating the value of
continuing this therapy until maximum response
was achieved.
Of the individual pretreatment factors, the
only one that had a significant influence on
response rate was the extent of disease (Table 2).
Patients with minimal disease (criteria reported
by Samuels et a113) had a 100% CR plus NED
rate, whereas those with bulky disease involving
lung and/or abdomen achieved CR plus NED in
20% (P = .03). Patients with poor performance
status and elevated levels of one or both tumor
markers had clearly lower response rates than
those with good performance status and normal
levels of tumor markers but the differences were
not statistically significant (P = .09). Neither
the site of origin of the primary tumor (testicular
or extragonadal) nor the histological subtype
influenced the responses observed.
Toxicities encountered with this program of
chemotherapy were moderate. Leukopenia was
the principal hematological toxicity, with nadir
WBC counts of less than 3,000/uL occurring in
28% and less than 1,000/uL in 2%. One death
from septicemia occurred in a patient with leuko-
penia. Chronic normocytic, normochromic ane-
mia (hemoglobin [Hb] < 10g/dL) developed in
28% of patients, particularly those who had
received extensive prior cisplatin chemotherapy
(ie, > four courses). Thrombocytopenia (platelet
nadir < 100,000/uL) occurred in 8% of patients
without any clinical sequelae.
Table 3 indicates the incidence and severity of
other toxicities accompanying this chemother-
apy. Moderate to severe nausea and vomiting
occurred in 79% of patients but was only difficult
to control with antiemetics in 9%. A degree of
stomatitis occurred in 42% of patients and was
predominantly related to the effects of methotrex-
ate. One patient developed severe renal dysfunc-
tion after therapy, but this occurred in conjunc-
29
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Table 3. Nonhematological Toxicities
Number of Grade of Toxicity (% of Patients)*
Toxicity Patients 0 1 2 3 4
Nausea/vomiting 46 0 22 70 9 0
Stomatitis 46 59 20 13 9 0
Skin 45 87 9 4 0 0
Alopecia 45 2 18 51 29 0
Diarrhea 46 89 7 4 0 0
Renal 46 89 9 0 2 0
Liver 46 91 7 2 0 0
*WHO criteria'1
tion with an episode of septicemia and shock. The
9% incidence of disturbed liver function after
therapy was minor and transitory and almost
certainly in part related to effects of the dissemi-
nated malignancy rather than drug toxicity.
In relation to these toxicities, reductions in the
dose of each of the drugs in the treatment
program was necessary in 18% of patients with-
out any apparent effect on the CR plus NED
rate.
z
z
0
0
C-
0
Of the 15 patients who achieved CR plus
NED, none has relapsed even with prolonged
follow-up and the median time of remission
exceeds 90 months (range, 63 to 99 months).
This contrasts with a median time to disease
progression of 9 months (range, 3 to 97 months)
for the 10 patients entering PR and nine of these
patients have relapsed. Figure 1 illustrates the
survival curve for the patient population from the
start of EAM therapy. All patients in CR plus
NED remain alive and well in excess of 5 years
whereas the median survival for the other pa-
tients was only 8 months (range, 2 to 97 months).
One patient in PR is a long-term survivor,
suggesting the apparent residual disease in this
patient is benign in nature.
DISCUSSION
Salvage chemotherapy for patients with germ
cell carcinoma refractory to primary chemother-
apy is gaining increasing acceptance as a worth-
while therapeutic approach. The 29% CR rate
0 10 20 30 40 50 60 70 80 90 100
MONTHS
Fig 1. Duration of survival for total patient population according to treatment response. X, complete response and NED
(N = 15); B, incomplete responders (N = 36). Log-rank analysis, P < .0001.
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achieved in this study is comparable to other
reports of the more effective drug combinations
but a particular feature of the present series is
that all patients have been followed for more
than 5 years and as no relapses have occurred,
cure is likely.s56'10
There can be little doubt that the present
patient population was a truly refractory one,
comprising 37 patients who had failed to achieve
complete remission with initial platinum-based
chemotherapy and were surgically unresectable,
while 14 patients had proven unresponsive
to retreatment with this chemotherapy after
initial CR.
Other studies have suggested that maximum
response in germ cell tumors is achieved with a
total of four courses of chemotherapy. 5'9 How-
ever, in this study the majority of complete
responders required five or more courses of ther-
apy, emphasizing that as long as there is evidence
of continuing response, chemotherapy should be
continued without arbitrary limit until maxi-
mum benefit is achieved.
This study is notable in that the three-drug
combination used did not contain cisplatin. Essen-
tially all other series have incorporated this agent
with one or more drugs, particularly etoposide,
and latterly, ifosfamide.,69."1'0 As the CR rate in
this series was equivalent to the other studies',
the value of including cisplatin in a regimen for
patients whose disease has already proven refrac-
tory to drug combinations containing this agent
must be questioned. Both Bosl et al6 and Williams
et al" have emphasized this point in their two
series of patients receiving cisplatin and etopo-
side, where no durable CRs were observed in
patients refractory to primary cisplatin-based
chemotherapy. Indeed, the only other study in
patients with truly refractory disease with a
comparable CR rate to the present one contained
both etoposide and ifosfamide in conjunction
with cisplatin, emphasizing doubts about the
value of cisplatin in this setting.5
To what extent each of the drugs in the present
program contributed to its success is difficult to
31
define. Certainly etoposide, as a single agent, has
proven active in late-stage germ cell malignancy
but CRs are uncommon and of short duration.7"• 5
Similarly, both dactinomycin and methotrexate
have demonstrated modest but short-lived activ-
ity in earlier studies."16 Therefore, it is likely that
all three drugs are contributing to the effective-
ness of the regimen. A synergistic effect is
possible, as the CR rate is higher than expected
from a purely additive effect and is of long-term
duration. While there is no experimental evi-
dence available to confirm this apparent synergis-
tic effect, it is noteworthy that all three drugs are
incorporated into the successful combination from
Charing Cross Hospital, London, England, whose
studies include patients with relatively refractory
and very advanced disease."7 The current multi-
ple-drug regimen from the Sloan-Kettering Insti-
tute, New York, NY also incorporates both
etoposide and dactinomycin. 2 All of this would
suggest that aggressive use of these agents, and
perhaps the substitution of ifosfamide for meth-
otrexate (the least active of these drugs), will
provide for even more successful salvage chemo-
therapy.
The toxicities encountered with this regimen
were not severe and certainly were less than those
seen with the programs containing cisplatin."
Indeed, the dose of etoposide used (75 mg/m2 for
3 days) was not as high as others incorporating
this drug and only 28% of patients experienced
leukopenia. Thus escalation of the dose of etopo-
side would be possible without producing prohib-
itive toxicity and with possible increased efficacy.
In conclusion, this study has demonstrated
that effective salvage chemotherapy for patients
with refractory germ cell carcinoma is possible
using completely noncrossresistant drugs to those
in primary induction programs and if complete
remission is achieved, long-term survival may
result. Nevertheless, there is still the potential for
further improvement and incorporation of drugs
such as ifosfamide, into the regimen. Evaluation
of the role of carboplatin in this setting may also
be appropriate.
APPENDIX
The following are other Institutions and Principal Investigators of the Australasian Germ Cell Trial Group 1979-83: Alan
Gray, Wellington Hospital, Wellington, New Zealand; Albert Freedman, Prince of Wales Hospital, Sydney; David Dalley, St.
Vincent's Hospital, Sydney and Ray Lowenthal, Royal Hobart Hospital, Hobart, Australia. Pathology Review Panel included
Richard Hollis, Royal North Shore Hospital, Sydney: John Bell, Mater Misericordiae, Brisbane, and Richard Sinclair, Peter
MacCallum Clinic, Melbourne, Australia.
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